AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03248492
Drug: DS-8201a
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as low, medium and high intravenous (IV) doses for Part 1 of the trial. The dose for Part 2 will be determined based on results from Part 1.
Trial: NCT03007303
Drug: Atypical Antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine: tablet ,5-20mg, Po q.d. Risperidone: tablet ,1-3 mg, Po q.d. Quetiapine: tablet ,100-400mg, Po b.i.d. ziprasidone : tablet ,40 -80mg, Po b.i.d.
Trial: NCT01719380
Drug: LGX818
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01719380
Drug: BYL719
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03713684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Trial: NCT03713684
Drug: Background therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lantus (Insulin Glargine), SC, once daily; OADs, administered as per investigator prescription and in accordance with local labeling.
Trial: NCT01134952
Drug: Mycophenolate to sirolimus switch
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus given for 3 months instead of mycophenolate at a starting dose equivalent of 1 mg sirolimus equal to 1000 mg of mycophenolate.
Trial: NCT01055301
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01055301
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00974311
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT00412841
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets identical to atorvastatin 40mg
Trial: NCT02071459
Drug: L-Threo DOPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: initial dose titration period (4 weeks) followed by 8 weeks at the max tolerated dose
Trial: NCT02071459
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: initial period (4 weeks) followed by 8 weeks
Trial: NCT03671070
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Low dose Boluses
Trial: NCT01305200
Drug: supersaturated calcium phosphate rinse
RxNorm normalized name: Phos Flur Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mouth rinse
Trial: NCT01634113
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo matching tiotropium
Trial: NCT03671070
Drug: Traditional management of shock
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Initial resuscitation: Push boluses of 20 cc/kg isotonic saline or colloid up to and over 60 cc/kg until perfusion improves or unless rales or hepatomegaly develop~2. Fluid refractory shock: Begin inotrope IV/IO. Use atropine/ketamine IV/IO/IM to obtain central access and airway if needed. Reverse cold shock by titrating central dopamine or, if resistant, titrate central epinephrine. Reverse warm shock by titrating central norepinephrine.~3. Catecholamine resistant shock: Begin hydrocortisone if at risk for absolute adrenal insufficiency.
Trial: NCT03102502
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline- driven standard medical treatment including statins,antiplatelet drugs（aspirin or Clopidogrel ）, anti-ischemic drugs （Nitroglycerin）
Trial: NCT01561690
Drug: Placebo; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT01403389
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mL of 0.9% Sodium Chloride IV fluid given as placebo in the operating room prior to organ reperfusion
Trial: NCT00967031
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03511703
Drug: Chemotherapy drugs+Iodized oil
RxNorm normalized name: calcium iodized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-arterial infusion chemotherapy for tumors, commonly used chemotherapy drugs include anthracyclines, platinum, etc.; chemotherapeutic drugs and embolic agents are mixed together and injected through the blood supply artery of the tumor. The most commonly used embolic agent for TACE treatment is a lipiodol emulsion. First infusion of some chemotherapy drugs, the general infusion time should not be \<20 min. Then another part of the chemotherapeutic drugs and lipiodol were mixed into emulsions for embolization. The amount of lipiodol is generally 5-20 ml, not more than 30 ml.
Trial: NCT06609993
Drug: intravenous rescue opioid analgesia using fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intraoperative rescue opioid analgesia using 1mcg/kg of fentanyl (Fentanyl WZF, POlfa Warsawa, Poland) )/ body weight when SPI value \> 15 baseline
Trial: NCT06609993
Drug: primary treatment of postoperative nausea and vomiting (PONV)
RxNorm normalized name: Pepto Nausea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dexamethasone ((Dexaven 4mg/ml, Jelfa, Poland) in a dose of 4 mg will be administered intravenously when incidence of PONV is observed
Trial: NCT06609993
Drug: secondary treatment of postoperative nausea and vomiting (PONV)
RxNorm normalized name: Pepto Nausea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (Ondansetron Accord 2mg/ml, 2 ml solution, Accord Healthcare Limited, Great Britain) in a dose of 4 mg will be administered intravenously when incidence of persistent PONV is observed despite the dexamethasone in a dose of 4 mg will be administration intravenously
Trial: NCT00951561
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg daily
Trial: NCT03483077
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT03459157
Drug: HIV prevention package including PrEP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All MSM enrolled will benefit from a comprehensive HIV prevention package including quarterly clinical examinations, screening and treatment of STIs, screening of HIV, PrEP (TDF 300 mg + FTC 200 mg), daily or on-demand, according the participant's choice, immunisation against hepatitis B, individualised peer-led support (for adherence and prevention), group discussions, condoms, and lubricants.
Trial: NCT04657068
Drug: ART0380
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive ART0380 by mouth either intermittently (either once daily 3 days on, 4 days off; days 2-4 and 9-11;or days 1-3 and 8-10) or continuously (once daily each day) in 21 day cycles.
Trial: NCT01424163
Drug: Single dose reduced
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 1 (Part A)
Trial: NCT01424163
Drug: Single dose standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 2 (Part A)
Trial: NCT01424163
Drug: Multiple Dose
RxNorm normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 3 (Part A)
Trial: NCT01424163
Drug: Multiple Dose
RxNorm normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B
Trial: NCT02746432
Drug: Hyper insulinemic euglycemic clamp
RxNorm normalized name: Hyper-Sal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After obtaining a baseline preoperative lab set blood glucose value, 2 U/kg bolus of insulin (Human regular insulin) to be administered IV followed by an infusion of 2 U/ kg/min.fiver - Ten minutes after starting the insulin infusion, and when the blood glucose is \<6.1 mmol /L (110 mg /dL). an Infusion of dextrose 20% supplemented with pottasium phosphate (30 mmol/L ) to be administered. In the operating room, blood glucose levels were measured every 5-15 minutes, and the dextrose infusion rate was adjusted to maintain arterial glycemia between 3.5 and 6.1 mmol/L (63-110 mg/dL). timed intra operative lab assessment to be obtained.
Trial: NCT00535756
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02697071
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive normal saline intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.
Trial: NCT01994837
Drug: ABT-199
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT00853294
Drug: Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule
RxNorm normalized name: chlorpheniramine polistirex / hydrocodone polistirex Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule, single dose fasting
Trial: NCT00853294
Drug: 5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tussionex® Pennkinetic® Extended Release Oral Suspension, single dose fasting
Trial: NCT00518544
Drug: administration of hydroxyehtyl starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: colloid is administered during operation according to blood loss.
Trial: NCT03022253
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:~Ibuprofen:~Dosage-10 mg/kg stat followed by 5 mg/kg/dose x 2 doses at 24 hours intervals Route- oral
Trial: NCT01262677
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matched to the active drug
Trial: NCT00607685
Drug: 5 Fluorouracil with hyaluronic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a subconjunctival injection of 0.1ml of a mixure of 5 Fluorouracil (50mg/ml) with hyaluronic acid (23mg/ml) once at enrollment into the study.
Trial: NCT01016678
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dummy pill comparator
Trial: NCT01212263
Drug: Step-up HP u FSH
RxNorm normalized name: STEP 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP u FSH (Fostimone 75 IU ,IBSA Institut Biochimique SA-CH 6903 Lugano) in doses of 37.5 IU (half ampole) im /day statrted from second day of the cycle for 7 days ,then increased to 75 IU for another 7 days ,then to 112.5 IU (one and half ampoule) untilleading follicle mean diameter reaches 18 mm
Trial: NCT00615602
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 700 mg/m2 IV push on day 1 every 4 weeks
Trial: NCT00615602
Drug: 5-fluoruracil
RxNorm normalized name: 1-(β-D-5-desoxyribofuranoxyl)-5-fluoruracil
DrugBank: Doxifluridine (DB12947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluoruracil 700 mg/m2 IV push on day 1 every 4 weeks
Trial: NCT03491969
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg, po, tid
Trial: NCT00153881
Drug: Capecitabine (Xeloda)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Neoadjuvant Chemotherapy:~Docetaxel every 3 weeks for 2 cycles Carboplatin every 3 weeks for 2 cycles with prophylactic antibiotics and antiemetics as needed.~Concomitant chemotherapy and radiation:~Docetaxel weekly for 5 doses without premedication Capecitabine orally, one dose prior to each fraction of irradiation (28 cycles).
Trial: NCT02508220
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: distilled water in nasal spray
Trial: NCT02707601
Drug: E/C/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150/150/200/10 mg fixed dose combination (FDC) tablet administered orally once daily
Trial: NCT02707601
Drug: F/R/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200/25/25 mg FDC tablet administered orally once daily
Trial: NCT01171807
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients assigned to placebo arm performed the same procedure as the patients assigned to the DEX 21-P group without loading in the Red Blood Cells the Dex 21-P
Trial: NCT04294953
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will receive a similar looking placebo capsule in the same time schedule. The placebo capsule will be prepared by hospital pharmacy to insure that active Duloxetine capsules will be indistinguishable from the placebo capsules contained starch
Trial: NCT04063475
Drug: cyanoacrylate tissue adhesive beside sutures
RxNorm normalized name: ethyl cyanoacrylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: using cyanoacrylate tissue adhesive for FGG fixation
Trial: NCT02707601
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90/400 mg FDC tablet administered orally once daily
Trial: NCT04687059
Drug: Placebo Option 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension for injection
Trial: NCT04687059
Drug: Placebo Option 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection
Trial: NCT02486276
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Trial: NCT02969239
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bolus administered norepinephrine 5mcg intravenously, if SBP \<90mmHg or 20% decrease from baseline
Trial: NCT04084184
Drug: HGP1602
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 10mg
Trial: NCT01901341
Drug: CB-5945
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01901341
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04398290
Drug: Inhaled nitric oxide (iNO)
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iNO Pulse 250 mcg/kg ideal body weight (IBW)/hour
Trial: NCT00869869
Drug: melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2.5 mg melatonin, by mouth, 1 per day, for 3-4 weeks
Trial: NCT00869869
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03585270
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered at the same infusion rate as clazosentan for up to 14 days.
Trial: NCT01021397
Drug: rHPIV3cp45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10\^5 TCID50 nasal drops
Trial: NCT01021397
Drug: rHPIV3cp45 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1X-L15 nasal drops
Trial: NCT03588130
Drug: EscharEx (5% EX-02 formulation)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active arm
Trial: NCT03588130
Drug: Non-surgical standard of care (NSSOC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Santyl (Enzymatic debridement) or commercially approved Hydrogel
Trial: NCT03167242
Drug: KAF156
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KAF156 comes in 100 mg tablets for oral administration. KAF156 was administered in combination with LUM-SDF once daily (QD) for 1, 2 or 3 days at 200 mg, 400 mg or 800 mg doses.
Trial: NCT01487083
Drug: Pomaglumetad methionil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT04477369
Drug: DWJ1439
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg single dose
Trial: NCT04477369
Drug: DWJ1464
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg single dose
Trial: NCT04477369
Drug: DWC202003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg single dose
Trial: NCT04477369
Drug: DWC202004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg single dose
Trial: NCT00467142
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02929329
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets
Trial: NCT02929329
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants were required to be optimally managed with standard of care therapies for chronic HF (eg, beta blockers, renin angiotensin aldosterone system inhibitors), consistent with regional clinical practice guidelines, unless contraindicated.
Trial: NCT00621101
Drug: 1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of 1 tablet Ezetrol(R) (10 mg ezetimibe), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
Trial: NCT00621101
Drug: 1 tablet Rapamune(R) (sirolimus), Wyeth Pharma, Germany
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus), 0-144 h blood sampling
Trial: NCT00467142
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03351361
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doublet of chemotherapy according to standard of care carboplatin (AUC 5) with a dose that will be capped to 700 mg and pemetrexed (500 mg/m²) over 4 to 6 hours every three weeks (restricted to non-squamous histology) or carboplatin (AUC 6) with a dose that will be capped to 700 mg and paclitaxel (90 mg/m²) D1 D8 D15 over 4 to 6 hours every 4 weeks, with a maximum of 4 cycles of carboplatin based doublet, and the possibility to use maintenance with pemetrexed.
Trial: NCT05153278
Drug: Intravenous drug
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment for iron deficiency treatment
Trial: NCT00703937
Drug: Standard Medical Care (SMC) for the treatment of IDA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01033422
Drug: CF101
RxNorm normalized name: CF101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CF101 1 or 2 mg tablets orally every 12 hours for 16 weeks
Trial: NCT01033422
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets orally every 12 hours for 16 weeks
Trial: NCT03368339
Drug: PR013 (0.045%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PR013 topical Ophthalmic Drops (0.045%)
Trial: NCT03368339
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle
Trial: NCT03160040
Drug: Minocycline IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study is an observational study. All participants were administered minocycline IV prior to enrollment in this study.
Trial: NCT01066520
Drug: Diclofenac gel
RxNorm normalized name: diclofenac Topical Gel
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 g, 3 times daily topical during 14 days
Trial: NCT01154036
Drug: Comparator: rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00926965
Drug: Conventional antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the subjects were randomized to the conventional antipsychotic group to maintain their original conventional antipsychotics
Trial: NCT01375959
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 placebo capsules orally twice a day for 6 weeks
Trial: NCT02947087
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive saline on day 0, 7, 14, and 21 days of transplantation
Trial: NCT02435121
Drug: SAR125844
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Concentrate for solution Route of administration: intravenous
Trial: NCT01253304
Drug: LY2189265
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) injection
Trial: NCT01327495
Drug: Testosterone 1% gel 1.25 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: testosterone 1% gel 1.25 g daily applied transdermally x 12 weeks
Trial: NCT01327495
Drug: Testosterone 1% gel 2.5 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone 1% gel 2.5 g daily applied transdermally x 12 weeks
Trial: NCT01327495
Drug: Testosterone 1% gel 5.0 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone 1% gel 5.0 g daily applied transdermally x 12 weeks
Trial: NCT01327495
Drug: testosterone 1% gel 15 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone 1% gel 15 g daily applied transdermally x 12 weeks
Trial: NCT01503385
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg by mouth twice daily for for 5-7 days before beginning radiation therapy; continued 7 days per week throughout radiation treatment (about 6 weeks).
Trial: NCT00307684
Drug: double blind placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo tablets once daily for 4 weeks
Trial: NCT00005108
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no